LifeStance Health Group, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-82.1% vs price
Base Case (Median)
-75.0% vs price
Bull Case (75th pct.)
-28.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $11.35 | -9.6% | High (40%) |
| PE Comparable | $2.89 | -76.9% | Medium (25%) |
| Graham Number | $3.39 | -72.9% | Medium (40%) |
| EV/EBITDA | $2.04 | -83.7% | Medium (20%) |
| EV/FCF | $10.88 | -13.3% | Medium (20%) |
| Earnings Power Value | $0.59 | -95.3% | Medium (50%) |
Based on 6 out of 8 methods, LFST appears overvalued at the current price of $12.55. The base case fair value of $3.14 implies 75.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.